23 nov: USA: Ordreindgang på varige goder overrasker markant positivt
23 nov: Bavarian melder om fuldt hus i studie af koppevaccine
23-11-2016 15:23:05

Bavarian Nordic Completes Enrollment of Phase 3 Non-inferiority Study of IMVAMUNE® Smallpox Vaccine

Relateret indhold
22 jan - 
Bavarian rider med på biotekbølge: Aktien stiger godt 5..
22 jan - 
Aktier/middag: Bavarian Nordic topper i rødt C25
19 jan - 
Fredagens aktier: William Demant tog føringen i positiv..
Relateret debat
13:13 - 
Pas nu på - den store anonyme broker vil de næste par d..
22 jan - 
Har været med på Bavarian siden kr. 46.80, såååeee erfa..
22 jan - 
Også jeg vil gerne rose dig runev1 for ærlighed. Det ma..

  • Second and final Phase 3 study to support a U.S. registration of liquid-frozen IMVAMUNE

COPENHAGEN, Denmark, November 23, 2016 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced the completion of enrollment of a Phase 3 clinical study designed to demonstrate non-inferiority between its investigational, non-replicating smallpox vaccine, IMVAMUNE and ACAM2000, the current U.S. licensed, and replicating smallpox vaccine. This is the second and final study agreed with the U.S. Food and Drug Administration (FDA) to support the registration of liquid-frozen IMVAMUNE. The first study, a lot consistency study in 4,000 healthy individuals, was successfully completed in 2015.

The Phase 3 non-inferiority study enrolled 440 subjects at a U.S. military garrison in South Korea led by the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) in collaboration with the U.S. Defense Health Agency. All subjects will have completed the study within second quarter of 2017, and top line data is anticipated in the second half of 2017.

Paul Chaplin, President & Chief Executive Officer of Bavarian Nordic, said: "Completion of enrolment of this study represents a significant milestone in the collaboration between Bavarian Nordic, and multiple federal agencies. IMVAMUNE has served as the cornerstone for our Company over the past decade and we will continue to work with the U.S. Government to meet their stated goal of protecting 66 million Americans who are in need of a safer smallpox vaccine. We look forward reporting these data and working with the authorities in the process towards U.S. licensure."

Bavarian Nordic has to-date delivered 28 million doses of liquid-frozen IMVAMUNE to the U.S. Strategic National Stockpile.

Federal funding acknowledgments

The Phase 3 study comparing the safety and immunogenicity of IMVAMUNE to ACAM2000 has been funded in whole or in part with Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under Contract No. HHSO100200700034C

About Bavarian Nordic

Bavarian Nordic is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases, based on the Company's live virus vaccine platform. Through long-standing collaborations, including a collaboration with the U.S. government, Bavarian Nordic has developed a portfolio of vaccines for infectious diseases, including the non-replicating smallpox vaccine, IMVAMUNE®, which is stockpiled for emergency use by the United States and other governments. The vaccine is approved in the European Union (under the trade name IMVANEX®) and in Canada. Bavarian Nordic and its partner Janssen are developing an Ebola vaccine regimen, which has been fast-tracked, with the backing of worldwide health authorities, and a vaccine for the prevention and treatment of HPV. Additionally, in collaboration with the National Cancer Institute, Bavarian Nordic has developed a portfolio of active cancer immunotherapies, including PROSTVAC®, which is currently in Phase 3 clinical development for the treatment of advanced prostate cancer. The company has partnered with Bristol-Myers Squibb for the potential commercialization of PROSTVAC. For more information visit www.bavarian-nordic.com or follow us on Twitter @bavariannordic.

Forward-looking statements

This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

Contacts

Rolf Sass Sørensen

Vice President Investor Relations (EU)

Tel: +45 61 77 47 43

Seth Lewis

Vice President Investor Relations (US)

Tel: +1 978 341 5271

Company Announcement no. 30 / 2016

2016-30-en


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Bavarian Nordic A/S via Globenewswire

Vedhæftet fil: 771658.pdf

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
19 jan
BAVA
Ham oraklet som spår kurs 150 har også ævlet om kurs 500 i Genmab de sidste par år og så kan man sel..
4
22 jan
BAVA
Det er så sygt. Har været med i flere år. Købte ekstra op på prostvac faldet. For 4 dage siden fik j..
3
22 jan
BAVA
det er baronen som er begyndt at købe
3
19 jan
BAVA
og reelt har du ikke sagt andet i mange år om bava.. om kurs 150 .. skal vi  snart se den ? du snakk..
3
19 jan
BAVA
hvad har manden gw ikke tage taget fejl med .. alle hans hunde spådomme ,plus at   manden er besat a..
3
19 jan
BAVA
Det danske biotekselskab Bavarian Nordic starter et fase 1-forsøg med en ny lægemiddelkandidat inden..
3
19 jan
BAVA
Bavarian er ikke i mineindustrien.
3
19 jan
BAVA
Sidst jeg var på denne side diskuterede man aktiernes fremtidsudsigter, potentialer, grafer, nyheder..
2
19 jan
BAVA
Reelt har intet ændret sig med Bavarian de senere mange år, andet end at tiden er gået.   Det er og ..
2
19 jan
BAVA
Nej, jeg var heller ikke klar over at kobber var blevet en del af deres produktion. Det er godt at B..
2

Aktier/tendens: Tryg kommer med lunkent regnskab i varmt marked

23-01-2018 08:44:18
Mens tirsdagens åbning tegner positiv, så kan Tryg halte lidt efter det generelle marked, efter at forsikringskoncernen har skudt regnskabssæsonen ind med tal for fjerde kvartal, der peger i flere retninger.Målt på det forsikringstekniske resultat slog Tryg akkurat analytikerforventningerne. Til gengæld haltede bundlinjen lidt efter forventningerne blandt andet som følge af en lidt skuffende inves..

Bavarian rider med på biotekbølge: Aktien stiger godt 5 pct.

22-01-2018 15:05:51
Bavarian Nordic er i forrygende form på børsen i København mandag eftermiddag, hvor aktien stiger med 5,3 pct. til 244,30 kr.Der er ikke umiddelbart selskabsspecifikke nyheder i markedet, der kan forklare fremgangen, men fokus er der i hvert fald til hele sektoren, efter at der er blevet annonceret to store handler i USA.Det kaster også udenlandsk interesse i retningen af Bavarian Nordic, hvor ude..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Bavarian rider med på biotekbølge: Aktien stiger godt 5 pct.
2
Genmab: Partner melder om vækst i Darzalex-salg på 86 pct.
3
Danske Bank/RBC: Konsensus for udlodninger efter 2018 er for høje
4
Amerikansk industrigigants aktie når laveste niveau siden 2011
5
Torm sætter tal på 2017 og udnytter optioner på to skibe - NY

Relaterede aktiekurser

Bavarian Nordic A/S 238,90 -2,7% Fald i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2018  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
23. januar 2018 14:32:43
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20180122.2 - EUROWEB3 - 2018-01-23 14:32:43 - 2018-01-23 14:32:43 - 1 - Website: OKAY